All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @jonnosunshine on TikTok · 21s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @jonnosunshine's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00So this is me just before I start my sixth tender. So at the moment I'm 115 kilos
  2. 0:08Currently wearing size 38 inch trousers and a weight
  3. 0:15Weight measurement of 116 centimeters. So fingers crossed we're off on the journey

Saxenda for weight loss: what day-one TikTok posts get wrong

Jonno

TikTok creator

54.5K viewsWatch on TikTok

Quick answer

The creator reports a starting weight of 115 kg and waist circumference of 116 cm, both of which exceed clinical thresholds for obesity-related cardiometabolic risk in adult males. Saxenda (liraglutide 3.0 mg) is a once-daily injectable GLP-1 receptor agonist with regulatory approval for chronic weight management in adults with a BMI of 30 or above, or 27 and above with a weight-related comorbidity. Phase 3 trial data supports average weight loss of 8 to 9% of body weight over 56 weeks, with significant individual variation in response.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Saxenda for weight loss: what day-one TikTok posts get wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Saxenda for weight loss: what day-one TikTok posts get wrong is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Saxenda for weight loss: what day-one TikTok posts get wrong" from Jonno. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator reports a starting weight of 115 kg and waist circumference of 116 cm, both of which exceed clinical thresholds for obesity-related cardiometabolic risk in adult males.

The reason this review is not generic is the source wording and the canonical claim label "glp1 beginning my weight loss using saxenda saxenda weightloss ma." In this clip, the useful excerpt is: "So this is me just before I start my sixth tender." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

A waist circumference above 102 cm in males is a WHO-recognised threshold for substantially increased cardiometabolic risk, separate from BMI alone.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator reports a starting weight of 115 kg and waist circumference of 116 cm, both of which exceed clinical thresholds for obesity-related cardiometabolic risk in adult males.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator reports a starting weight of 115 kg and waist circumference of 116 cm, both of which exceed clinical thresholds for obesity-related cardiometabolic risk in adult males. Saxenda (liraglutide 3.0 mg) is a once-daily injectable GLP-1 receptor agonist with regulatory approval for chronic weight management in adults with a BMI of 30 or above, or 27 and above with a weight-related comorbidity. Phase 3 trial data supports average weight loss of 8 to 9% of body weight over 56 weeks, with significant individual variation in response.
  • Saxenda (liraglutide 3.0 mg) produced mean weight loss of 8.4 kg more than placebo over 56 weeks in the SCALE trial (Pi-Sunyer et al., 2015, NEJM), roughly 8% of starting body weight.
  • A waist circumference above 102 cm in males is a WHO-recognised threshold for substantially increased cardiometabolic risk, separate from BMI alone.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Saxenda (liraglutide 3.0 mg) produced mean weight loss of 8.4 kg more than placebo over 56 weeks in the SCALE trial (Pi-Sunyer et al., 2015, NEJM), roughly 8% of starting body weight.
  • A waist circumference above 102 cm in males is a WHO-recognised threshold for substantially increased cardiometabolic risk, separate from BMI alone.
  • Around 40% of liraglutide users in phase 3 trials reported gastrointestinal side effects, particularly nausea, most common during the titration phase.
  • Liraglutide is injected once daily and requires gradual dose titration from 0.6 mg to 3.0 mg over four to five weeks.
  • Saxenda and semaglutide (Ozempic, Wegovy) are different molecules with different dosing schedules and are not interchangeable, despite both being GLP-1 receptor agonists.
  • Roughly 37% of people in the SCALE trial did not achieve even 5% body weight loss on liraglutide, so non-response is a real and common outcome.
  • Waist-to-height ratio is increasingly supported over BMI as a single cardiometabolic risk marker in adults (Ashwell et al., 2012, Nutrition Research Reviews).

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @jonnosunshine actually say?

Not much, honestly, and that's fine. This is a day-one check-in. He says he's starting "sixth tender" (almost certainly a speech-to-text mangle of Saxenda), weighs 115 kilos, wears 38-inch trousers, and has a waist measurement of 116 centimeters. That's it. No dosing claims, no miracle promises, just a starting-line selfie in video form.

The baseline metrics he gives are actually useful data points. A waist circumference of 116 cm in a male sits well above the 102 cm threshold that clinical guidelines use to flag substantially elevated cardiometabolic risk. He's not just sharing his weight journey for content; whether he knows it or not, he's documenting a genuinely high-risk metabolic starting point.

Does the science back this up?

He didn't really make scientific claims, so there's nothing to fact-check against the literature here. But starting Saxenda (liraglutide 3.0 mg) at a BMI that almost certainly clears the prescribing threshold is clinically appropriate, and the evidence base for liraglutide at this weight range is real.

The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) found liraglutide 3.0 mg produced an average 8.4 kg greater weight loss than placebo over 56 weeks in non-diabetic adults with obesity. That's meaningful but not dramatic. Importantly, around 63% of participants lost at least 5% of body weight, meaning a meaningful minority don't respond strongly. For someone at 115 kg, 5% is about 5.75 kg. Realistic, not transformative on its own.

What did they get wrong (or right)?

He didn't get anything factually wrong, because he barely made any factual claims. Credit where it's due: not over-promising on day one is actually better than most GLP-1 content on TikTok, where creators routinely inflate expected outcomes or treat these medications as effortless fixes.

The one thing worth flagging is the speech-to-text rendering of "sixth tender" for Saxenda. It sounds trivial, but misspelled or misheard drug names in viral content do contribute to confusion, especially when people search those terms. Saxenda is liraglutide; it is a different molecule from semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro). They work on overlapping but distinct receptor pathways, and they are not interchangeable. His content doesn't claim otherwise, but it's worth stating plainly for anyone landing here from a search.

What should you actually know?

Waist circumference matters more than most people realise. The 116 cm measurement he mentions is above the threshold where visceral adiposity independently predicts cardiovascular and metabolic disease risk, separate from total body weight. Lean mass, where fat sits, and how metabolically active that fat is all matter. Waist-to-height ratio is increasingly favoured over BMI alone in research settings (Ashwell et al., 2012, Nutrition Research Reviews).

Saxenda requires dose titration over several weeks, starting at 0.6 mg and working toward 3.0 mg. Side effects, primarily nausea and gastrointestinal discomfort, are common in early weeks and are the main reason people discontinue. The SCALE trial recorded GI adverse events in around 40% of the liraglutide group. Anyone watching this and considering starting should know that week one rarely looks like the results reels they've seen elsewhere.

  • Liraglutide is injected once daily, unlike weekly semaglutide
  • It works by mimicking GLP-1, a gut hormone that slows gastric emptying and reduces appetite signalling
  • It is not a cure for obesity and does not work the same way in everyone

The bottom line

This video is a nothing-burger in terms of medical claims, which is actually a compliment in the GLP-1 content space. He's documenting a real starting point with real numbers. The metrics he shares reflect a genuine cardiometabolic risk profile, and Saxenda is a regulated, evidence-supported medication for his stated situation. Follow the journey with realistic expectations: 5 to 10% body weight loss over 6 to 12 months is the realistic range, not the transformation content that tends to dominate this hashtag.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Jonno · TikTok creator

54.5K views on this video

beginning my weight loss using Saxenda. #saxenda #weightloss #maleweightloss #dadbod #day1

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about saxenda (liraglutide 3.0 mg) produced mean weight loss of 8.4?

Saxenda (liraglutide 3.0 mg) produced mean weight loss of 8.4 kg more than placebo over 56 weeks in the SCALE trial (Pi-Sunyer et al., 2015, NEJM), roughly 8% of starting body weight.

What does the video say about a waist circumference above 102 cm in males?

A waist circumference above 102 cm in males is a WHO-recognised threshold for substantially increased cardiometabolic risk, separate from BMI alone.

What does the video say about around 40% of liraglutide users in phase 3 trials reported?

Around 40% of liraglutide users in phase 3 trials reported gastrointestinal side effects, particularly nausea, most common during the titration phase.

What does the video say about liraglutide?

Liraglutide is injected once daily and requires gradual dose titration from 0.6 mg to 3.0 mg over four to five weeks.

What does the video say about saxenda?

Saxenda and semaglutide (Ozempic, Wegovy) are different molecules with different dosing schedules and are not interchangeable, despite both being GLP-1 receptor agonists.

What does the video say about roughly 37% of people in the scale trial did not?

Roughly 37% of people in the SCALE trial did not achieve even 5% body weight loss on liraglutide, so non-response is a real and common outcome.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Jonno, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.